← All trials
NCT05523570
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 22, 2022
- Primary completion
- Feb 7, 2023
- Completion date
- Apr 5, 2023
- First posted
- Aug 31, 2022
- Last posted
- Aug 31, 2022
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Henovcom Bioscience Co. Ltd.Lead sponsor
- Frontage Laboratories, Inc.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.